Presentation is loading. Please wait.

Presentation is loading. Please wait.

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis  Howard Sofen, MD, Stacy.

Published byErika Rožman Modified over 6 years ago

Similar presentations

Presentation on theme: "Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis  Howard Sofen, MD, Stacy."— Presentation transcript:

1 Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis  Howard Sofen, MD, Stacy Smith, MD, Robert T. Matheson, MD, Craig L. Leonardi, MD, Cesar Calderon, PhD, Carrie Brodmerkel, PhD, Katherine Li, MS, Kim Campbell, PhD, Stanley J. Marciniak, MBA, Yasmine Wasfi, MD, PhD, Yuhua Wang, PhD, Philippe Szapary, MD, James G. Krueger, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 133, Issue 4, Pages (April 2014) DOI: /j.jaci Copyright © 2014 The Authors Terms and Conditions

2 Fig 1 Proportion of patients achieving at least a 75% improvement in Psoriasis Area and Severity Index (PASI 75) response (A) or a PASI 90 response (B) from baseline to week 24. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

3 Fig 2 A, Clinical response to a single dose of 10 mg of guselkumab administered at baseline. B, Clinical response to a single dose of 300 mg of guselkumab administered at baseline. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

4 Fig 3 Histologic evaluation of nonlesional and lesional skin at baseline and week 12 after subcutaneous injection of 300 mg of guselkumab. CD3, T cell; CD11c, myeloid DC; H&E, hematoxylin and eosin; KRT16, keratin 16. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

5 Fig 4 Evaluation of mean epidermal thickness and T-cell (CD3) and myeloid DC (CD11c) expression from lesional skin biopsy specimens at baseline and after guselkumab or placebo treatment at weeks 1 and 12. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

6 Fig 5 A, Expression of KRT16, IFN-γ, IL-17F, and LCN2 mRNA at baseline and week 12 in lesional and nonlesional biopsy specimens from patients treated with high-dose (100 mg + 300 mg) guselkumab compared with placebo. B, Microarray expression of 1224 transcripts of nonlesional skin at baseline versus lesional skin at baseline and at weeks 1 and 12 after guselkumab treatment. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

7 Fig 6 Serum analyses of circulating IL-17A levels in guselkumab-treated responders (PASI 50 response at week 12) at baseline and at weeks 1 and 12 compared with the placebo-treated group. P values measure the significant difference in posttreatment compared with baseline values. *P = .031 and **P = Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

Download ppt "Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis  Howard Sofen, MD, Stacy."

Similar presentations

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.
Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in.

Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in.
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 
An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis  Mutasem M. Rawas-Qalaji,

Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis  Mutasem M. Rawas-Qalaji,
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,
Shinji Noda, MD, PhD, James G

Shinji Noda, MD, PhD, James G
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,
Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis  Tali Czarnowicki, MD, Dana Malajian, BA, Avner Shemer,

Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis  Tali Czarnowicki, MD, Dana Malajian, BA, Avner Shemer,

Similar presentations

Ads by Google